Vical Incorporated (VICL) Major Shareholder Armistice Capital, Llc Acquires 145,297 Shares of Stock

Vical Incorporated (NASDAQ:VICL) major shareholder Armistice Capital, Llc acquired 145,297 shares of the business’s stock in a transaction that occurred on Wednesday, June 13th. The shares were purchased at an average cost of $1.07 per share, with a total value of $155,467.79. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website. Major shareholders that own at least 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Armistice Capital, Llc also recently made the following trade(s):

  • On Monday, June 11th, Armistice Capital, Llc acquired 368,705 shares of Vical stock. The shares were purchased at an average cost of $1.18 per share, with a total value of $435,071.90.

NASDAQ VICL traded up $0.12 during trading on Thursday, hitting $1.19. 19,447 shares of the company’s stock were exchanged, compared to its average volume of 212,781. The company has a market cap of $26.30 million, a price-to-earnings ratio of -1.14 and a beta of 1.22. Vical Incorporated has a fifty-two week low of $1.02 and a fifty-two week high of $3.70.

Vical (NASDAQ:VICL) last issued its earnings results on Thursday, May 3rd. The biotechnology company reported ($0.29) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.17) by ($0.12). The business had revenue of $0.72 million for the quarter, compared to analyst estimates of $2.10 million. Vical had a negative return on equity of 32.93% and a negative net margin of 144.80%. equities research analysts forecast that Vical Incorporated will post -1.08 EPS for the current year.

Several research firms recently weighed in on VICL. ValuEngine raised shares of Vical from a “sell” rating to a “hold” rating in a research report on Wednesday, May 2nd. Zacks Investment Research raised shares of Vical from a “hold” rating to a “buy” rating and set a $1.75 price objective for the company in a research report on Saturday, March 17th. Finally, HC Wainwright set a $5.00 price objective on shares of Vical and gave the stock a “buy” rating in a research report on Monday, May 7th.

A number of hedge funds and other institutional investors have recently modified their holdings of VICL. Ariel Investments LLC increased its position in shares of Vical by 9.6% during the 4th quarter. Ariel Investments LLC now owns 637,913 shares of the biotechnology company’s stock valued at $1,167,000 after purchasing an additional 55,669 shares during the last quarter. Geode Capital Management LLC boosted its holdings in Vical by 195.0% in the fourth quarter. Geode Capital Management LLC now owns 111,688 shares of the biotechnology company’s stock worth $204,000 after acquiring an additional 73,822 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in Vical by 17.2% in the fourth quarter. Renaissance Technologies LLC now owns 677,229 shares of the biotechnology company’s stock worth $1,239,000 after acquiring an additional 99,420 shares in the last quarter. Millennium Management LLC bought a new stake in Vical in the fourth quarter worth $256,000. Finally, Sabby Management LLC bought a new stake in Vical in the fourth quarter worth $503,000. 44.44% of the stock is owned by hedge funds and other institutional investors.

Vical Company Profile

Vical Incorporated engages in the research and development of biopharmaceutical products based on its DNA delivery technologies for the prevention and treatment of serious or life-threatening diseases. It is developing various DNA-based vaccines and other therapeutics, such as VCL-HB01 therapeutic vaccine for herpes simplex virus-2 that is in Phase II clinical trial to prevent and protect against lesion recurrence; VL-2397 antifungal program, which is in Phase I clinical trial for the treatment of invasive fungal infections; and CyMVectin prophylactic vaccine for CMV that is in preclinical stage for the prevention of fetal transmission during pregnancy.

Receive News & Ratings for Vical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply